Do you want to read an article? Please log in or register.
Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial
Macular Diseases
Related content
Macular Diseases
Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT)
JAMA Ophthalmol.
Bavinger JC, Ying GS, Daniel E, Grunwald JE, Maguire MG, Comparison of Age-Related Macular Degeneration Treatments Trials Research Group.
doi: 10.1001/jamaophthalmol.
COMMENTED
Macular DiseasesRetinal Diseases
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Ophthalmology.
Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group
doi: 10.1016/j.ophtha.
Macular Diseases
Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial
JAMA Ophthalmol.
Ramakrishnan MS, Yu Y, VanderBeek BL
doi: 10.1001/jamaophthalmol.2019.4577.
Macular Diseases
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results
Ophthalmology.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group., Writing Committee:., Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd
doi: 10.1016/j.ophtha.2020.01.029.
COMMENTED
Macular Diseases
Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
doi: 10.1016/j.ophtha.2019.11.004.
RECOMMENDED
Macular Diseases
Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
doi: 10.1016/j.ophtha.2019.11.016.
RECOMMENDED
LensesMacular Diseases
Follow up at 5 Years of Non-Fibrotic Scars in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Ophthalmology.
Daniel E, Ying GS, Kim BJ, Toth CA, Ferris F 3rd, Martin DF, Grunwald JE, Jaffe GJ, Dunaief JL, Pan W, Maguire MG; Comparison of Age-related macular degeneration Treatments Trials
doi: 10.1016/j.ophtha.2018.11.020.
Macular Diseases
Association of 2-Year Progression Along the AREDS AMD Scale and Development of Late Age-Related Macular Degeneration or Loss of Visual Acuity: AREDS Report 22
JAMA Ophthalmol.
Vitale S, Agrón E, Clemons TE, Keenan TDL, Domalpally A, Danis RP Jr, Chew EY
doi: 10.1001/jamaophthalmol.2020.0824.
Macular Diseases
Antiplatelet and anticoagulant drugs do not affect visual outcome in neovascular age-related macular degeneration in the BRAMD trial
Am J Ophthalmol.
Buitendijk GHS, Schauwvlieghe AME, Vingerling JR, Schlingemann RO, Klaver CCW; comparing Bevacizumab to Ranibizumab in Age-related Macular Degeneration (BRAMD) trial research group
doi: 10.1016/j.ajo.2018.01.003.